Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer

Cancer Medicine

Volumn 2, Issue 6, 2013, Pages 916-924

  Liew, Mun Sem ^a,b,c   Sia, Joseph ^a   Starmans, Maud H W ^d,e   Tafreshi, Ali ^a   Harris, Sam ^a   Feigen, Malcolm ^a   White, Shane ^a   Zimet, Allan ^a   Lambin, Philippe ^e   Boutros, Paul C ^d   Mitchell, Paul ^a   John, Thomas ^a,b  

^a AUSTIN HEALTH   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN/PACLITAXEL; CISPLATIN/ETOPOSIDE; CONCURRENT CHEMORADIOTHERAPY; LOCALLY ADVANCED; NON-SMALL CELL LUNG CANCER; STAGE III;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 84905485981     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.142     Document Type: Article

References (34)